NCT02467946View on ClinicalTrials.gov

Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 14, 2016

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions
Clinical EfficacySafety
Interventions
DRUG

Adcetris-Levact

Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.

Trial Locations (1)

06000

Centre Antoine Lacassagne, Nice

All Listed Sponsors
collaborator

Millennium: The Takeda Oncology Company

INDUSTRY

lead

Centre Antoine Lacassagne

OTHER

NCT02467946 - Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient | Biotech Hunter | Biotech Hunter